Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, has announced that it has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to US$1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialization of zumilokibart.
Latham & Watkins LLP is advising Apogee in the strategic financing with a team led by partners Haim Zaltzman, Todd Trattner, and Dan Van Fleet, with associates Jing Cao and William Lane. Advice was also provided on tax matters by partner Eric Cho.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
